Ultra-low frequency variants as low as 0.01% VAF, including key AML MRD targets such as NPM1
Guideline-driven gene content
16 key AML-associated genes including longer, ultra-low frequency FLT3-ITDs over 300bp long
Interpret NGS Analysis Software on-premises or on-cloud enables visualisation of SNVs, indels and ITDs MRD dynamics over time
Rapid, streamlined workflow with Universal NGS Complete Workflow Solution

The SureSeq™ Myeloid MRD Plus Panel delivers

The SureSeq™ Myeloid MRD Plus Panel has been designed in collaboration with leading cancer experts and in accordance with the European LeukemiaNet (ELN) recommendations [1,2] to offer a single, cost-effective NGS assay to investigate MRD in AML samples. The panel content incorporates key genes for assessing AML, including genes implicated in MPN and MDS, to investigate secondary AML progression.

In addition, genes related to research on potential drug response are included for truly comprehensive and informative sample analysis.

Utilising SureSeq’s intelligent panel design capabilities, the Myeloid MRD Plus Panel surpasses the typical sensitivities offered by alternative NGS panels to accurately detect SNVs, indels and internal tandem duplications (ITDs) down to 0.01% VAF.

Gene targets

Gene	*Exons*
CSF3R	13–17
MPL	10
SF3B1	13–16
IDH1	4
KIT	2,8-11,13,17
NPM1	11
JAK2	12, 14
FLT3	13-15, and 20
IDH2	4, 5
TP53	2–11 (and 2 ex10 in non-MANE transcripts)
CALR	9
RUNX1	5-9 (and 5 in non-MANE transcript)
CEBPA	1
KRAS	2-3
NRAS	2-3
WT1	7, 9

More details

Discover more variants with ultra-low detection as low as 0.01% VAF

16 AML clinical research samples:

100% concordance with a comparator panel for key variants

Identified 5 previously undetected clinically-relevant variants

Figure 1: In a cohort of 16 AML clinical research samples with detected variants, SureSeq™ Myeloid MRD Plus Panel: displayed 100% concordance with known variants from a comparator panel; identified 5 previously undetected clinically-relevant variants.

Interrogate an expansive range of biomarkers, such as large FLT3-ITDs, detected at ultra-low frequencies in a single assay.

By leveraging our expertise in hybrid capture technology and sequence identification analysis, the SureSeq Myeloid MRD Plus NGS Panel can detect large FLT3-ITDs, in excess of 300bp, so you don’t miss actionable insights

Variant	Expected Frequency: 0.05%		Negative Control
HGVSc	Read Depth	Observed VAF (%)	Read Depth	Observed VAF (%)
FLT3 ITD-300	22,146	0.05	21,686	0.00

Gene	HGVSc	Length	Read Depth	Observed VAF (%)
FLT3	FLT3:n.1873_1998dup	216	22,146	0.08
	FLT3:n.1946_1947ins (183bp)	183	26,238	0.04
	FLT3:n.1664-77_1664-15dup	63	20,543	0.05

Data generated using the SureSeq Myeloid MRD Panel in combination with the Universal NGS Workflow Solution V2 and Interpret NGS Analysis Software highlights the detection of a 300 bp FLT3-ITD as well as 3 examples of FLT3-ITD detection in orthogonally validated research samples.

Figure 2: SureSeq™ Myeloid MRD Plus Panel detection of a 300 bp FLT3-ITD as well as 3 examples of FLT3-ITD detection in orthogonally validated research samples.

Figure 3: SureSeq™ Myeloid MRD Plus Panel detection of a 300 bp FLT3-ITD as well as 3 examples of FLT3-ITD detection in orthogonally validated research samples.

Figure 4: Interpret NGS Analysis Software enables easy visualization of genetic changes across multiple timepoints in MRD sample studies.

Figure 5: Example coverage profile of target regions in the SureSeq™ Myeloid MRD Panel

Figure 6: FLT3-ITDs of various sizes and even regions containing multiple ITDs can be confidently detected. ITD sizes are [A] 174 bp, [B] 225 bp, [C] 195 bp with additional 6 bp, [D] 120 bp, [E9 168 bp with additional 69 bp.

References

[1] European LeukemiaNET. Available at: www.leukemia-net.org.

[2] Döhner et al Blood. 2022 ;140(12):1345-1377

Disclaimer

SureSeq™: For Research Use Only, not for use in diagnostic procedures. Product availability may vary from country to country and is subject to varying regulatory requirements. Contact your local representatives for availability.

Manufacturer and Trademarks: SureSeq™(Oxford Gene Technology IP Limited)

Technical specifications

Technical information

Feature	Specification
Number of targets	53 hotspot exons from 16 genes
Panel size	8.9kb targeted; 12.4kb baited
Mean target coverage	Up to 20,000x
Limit of detection	0.01% VAF
Variant types	SNV, indel, ITDs
Sample type	Whole blood; bone marrow
Hands-on time	3h14min ultra-low workflow
DNA input recommended	400ng (2x200ng) high quality DNA
	Samples per run
NextSeq 500 High Output	16
NextSeq 2000 P3	48
NextSeq 2000 P4	72
NovaSeq^® SP	32
NovaSeq S1	64

Ordering information

Product	Contents	Cat. No.
SureSeq Myeloid MRD Plus Complete NGS Workflow Solution V2 (48)	Enrichment baits sufficient for 12 x 4-samples pools (48 samples total, run in duplicate). Bundle of 1 x Universal Library Preparation Kit (96) containing PCR primers and enzymes. 1 x Universal Hybridisation & Wash Kit V2 (96). 1 x Pre-PCR Universal Bead Kit (96). 1 x Post-PCR Universal Bead Kit (96). 1 x Universal Index Adapter Kit (96).	780145-48
SureSeq Myeloid MRD Plus NGS Panel (48)	Enrichment baits sufficient for 12 x 4-samples pools (48 samples total, run in duplicate)	770045-48
Universal NGS Workflow Solution V2	Bundle of 1 x Universal Library Preparation Kit (96) containing PCR primers and enzymes, 1 x Universal Hybridisation & Wash Kit V2 (96). 1 x Pre-PCR Universal Bead Kit (96). 1 x Post-PCR Universal Bead Kit (96). 1 x Universal Index Adapter Kit (96)	770510-96